| Market Cap | 48.67B | P/E | 21.40 | EPS this Y | -28.10% | Ern Qtrly Grth | 6.50% |
| Income | 149.92B | Forward P/E | 20.26 | EPS next Y | 102.40% | 50D Avg Chg | -3.00% |
| Sales | 4.41T | PEG | 9,101.88 | EPS past 5Y | 51.30% | 200D Avg Chg | -1.00% |
| Dividend | 588.00% | Price/Book | 0.01 | EPS next 5Y | 1.10% | 52W High Chg | -11.00% |
| Recommedations | - | Quick Ratio | 0.64 | Shares Outstanding | 1.58B | 52W Low Chg | 22.00% |
| Insider Own | 0.03% | ROA | 2.05% | Shares Float | 1.55B | Beta | 0.50 |
| Inst Own | 44.52% | ROE | 2.04% | Shares Shorted/Prior | -/- | Price | 30.60 |
| Gross Margin | 66.07% | Profit Margin | 3.40% | Avg. Volume | 11,854 | Target Price | - |
| Oper. Margin | 15.92% | Earnings Date | Oct 31 | Volume | 64 | Change | 0.00% |
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.